Tassal Tasmanian Salmon, an Australian salmon farming company, backed away from plans to dump treated wastewater from salmon pens into...
A three-month pilot period allowed Veolia to test on location
Veolia Water Solutions & Technologies will design and commission a biological waste water treatment plant to treat the effluents of an existing specialized tablet and capsule pharmaceutical manufacturing site. Veolia will use a core AnoxKaldnes MBBR biological treatment to meet the stringent local water discharge regulations.
According to Veolia, the client is one of the largest pharmaceutical companies in the world, with more than 80 manufacturing sites. It has awarded Veolia a contract to supply, build and start up a biological wastewater plant for its pharmaceutical manufacturing facility.
AnoxKaldnes MBBR solution is a moving bed biofilm reactor that operates continuously using specific plastic media to grow biofilm, and provides effective biochemical oxygen demand removal capability, as well as ammonia and nitrogen removal. The MBBR plant is coupled with a downstream dissolved air flotation unit designed to clarify water and remove the high total suspended solids content.
The plant’s sludge volume will be reduced by a sludge-dewatering unit that will concentrate the biomass up to 20% dry solids.
Veolia has offered the client a pilot testing period of 3 months, which has enabled it to precisely define the effluent process treatment that will meet and exceed the discharge regulation. The pilot unit installed on-site is fully containerized with all equipment required to carry out a test remotely. According to Veolia, it has helped the project to move forward more quickly than usual, since it was able to treat the exact complex effluent as it came from a variety of manufacturing processes.